5-HTP hypothesis of schizophrenia

Medical Hypotheses

Volumn 82, Issue 1, 2014, Pages 20-23

  Fukuda, K ^a  

^a Soka Clinic of Psychosomatic Medicine   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYTRYPTOPHAN; ADRENOCHROME; AMINE OXIDASE (FLAVIN CONTAINING); AROMATIC LEVO AMINO ACID DECARBOXYLASE; DOPAMINE; GLUTAMIC ACID; KYNURENIC ACID; KYNURENINE; PROSTAGLANDIN E1; TRYPTOPHAN HYDROXYLASE 1; TRYPTOPHAN HYDROXYLASE 2; UNCLASSIFIED DRUG;

ARGENTAFFIN CELL; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; HUMAN; INTRAUTERINE INFECTION; LIVER METABOLISM; NEGATIVE FEEDBACK; NEUROTRANSMISSION; SCHIZOPHRENIA; TRYPTOPHAN BRAIN LEVEL; TRYPTOPHAN METABOLISM;

5-HYDROXYTRYPTOPHAN; BRAIN; FEEDBACK, PHYSIOLOGICAL; HUMANS; MODELS, BIOLOGICAL; SCHIZOPHRENIA; SEROTONIN; TRYPTOPHAN HYDROXYLASE;

EID: 84890881480     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.10.026     Document Type: Article

References (31)

1. Walther D.J., Peter J.U., Bashammakh S., et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 2003, 299:76.
2. Sakowski S.A., Geddes T.J., Thomas D.M., Levi E., Hatfield J.S., Kuhn D.M. Differential tissue distribution of tryptophan hydroxylase isoforms 1 and 2 as revealed with monospecific antibodies. Brain Res 2006, 1085:11-18.
3. Zill P., Büttner A., Eisenmenger W., Müller J., Möller H.J., Bondy B. Predominant expression of tryptophan hydroxylase 1 mRNA in the pituitary: a postmortem study in human brain. Neuroscience 2009, 159:1274-1282.
4. Zaboli G., Jönsson E.G., Gizatullin R., Asberg M., Leopardi R. Tryptophan hydroxylase-1 gene variants associated with schizophrenia. Biol Psychiatry 2006, 60:563-569.
5. Anttila S., Kampman O., Illi A., Rontu R., Lehtimäki T., Leinonen E. Association between 5-HT2A, TPH1 and GNB3 genotypes and response to typical neuroleptics: a serotonergic approach. BMC Psychiatry 2007, 7:22.
6. Watanabe Y., Nunokawa A., Kaneko N., Someya T. The tryptophan hydroxylase 1 (TPH1) gene and risk of schizophrenia: a moderate-scale case-control study and meta-analysis. Neurosci Res 2007, 59:322-326.
7. Saetre P., Lundmark P., Wang A., et al. The tryptophan hydroxylase 1 (TPH1) gene, schizophrenia susceptibility, and suicidal behavior: a multi-centre case-control study and meta-analysis. Am J Med Genet B Neuropsychiatr Genet 2010, 153B:387-396.
8. Higashi S., Ohnuma T., Shibata N., Higashi M., Matsubara Y., Arai H. No genetic association between tryptophan hydroxylase 2 gene polymorphisms and Japanese schizophrenia. Psychiatr Genet 2007, 17:123.
9. Grimelius L. Methods in neuroendocrine histopathology, a methodological overview. Ups J Med Sci 2008, 113:143-260.
10. John Lacky. A Dictionary of Biomedicine: Oxford University Press; 2012.
11. Meyer T., Brinck U. Differential distribution of serotonin and tryptophan hydroxylase in the human gastrointestinal tract. Digestion 1999, 60:63-68.
12. Glassman A. Blood barrier to 5-HTP. N Engl J Med 1968, 278:281.
13. Khandaker G.M., Zimbron J., Lewis G., Jones P.B. Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies. Psychol Med 2013, 43:239-257.
14. Brown A.S. Exposure to prenatal infection and risk of schizophrenia. Front Psychiatry 2011, 2:63.
15. Niklasson B., Samsioe A., Blixt M., et al. Prenatal viral exposure followed by adult stress produces glucose intolerance in a mouse model. Diabetologia 2006, 49:2192-2199.
16. Bleuler M. Endokrinologische Psychiatrie. Stuttgart 1954, p.5.
17. Fukuda K. Possible mechanisms of panic attack and schizophrenia via APUD system. Med Hypotheses 2002, 58:123-126.
18. Bigelow L.B., Walls P., Gillin J.C., Wyatt R.J. Clinical effects of L-5-hydroxytryptophan administration in chronic schizophrenic patients. Biol Psychiatry 1979, 14:53-67.
19. Bogdanski D.F., Weissbach H., Undenfriend S. Pharmacological studies with the serotonin precursor, 5-hydroxytriptophan. J Phamacol Exp Ther 1958, 122:182-194.
20. Mills J.A. Hallucinogens as hard science. the adrenochrome hypothesis for the biogenesis of schizophrenia. Hist Psychol 2010, 13:178-195.
21. Horrobin D.F. Schizophrenia as a prostaglandin deficiency disease. Lancet 1977, 1:936-937.
22. Horrobin D.F., Ally A.I., Karmali R.A., Karmazyn M., Manku M.S., Morgan R.O. Prostaglandins and schizophrenia: further discussion of the evidence. Psychol Med 1978, 8:43-48.
23. Horrobin D.F. Schizophrenia: a biochemical disorder?. Biomedicine 1980, 32:54-55.
24. Glen A.I., Cooper S.J., Rybakowski J., Vaddadi K., Brayshaw N., Horrobin D.F. Membrane fatty acids, niacin flushing and clinical parameters. Prostaglandins Leukot Essent Fatty Acids 1996, 55:9-15.
25. Erhardt S., Blennow K., Nordin C., Skogh E., Lindström L.H., Engberg G. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett 2001, 131:96-98.
26. Erhardt S., Schwieler L., Nilsson L., Linderholm K., Engberg G. The kynurenic acid hypothesis of schizophrenia. Physiol Behav 2007, 92:203-209.
27. Udenfriend S., Weissbach H. Turnover of 5-hydroxytryptamine (serotonin) in tissue. Proc Soc Exp Biol Med 1958, 97:748-751.
28. Udenfriend S., Weissbach H., Bogdanski D.F. Increase in tissue serotonin following administration of its precursor 5-hydroxytryptophan. J Biol Chem 1957, 224:803-810.
29. Wa T.C., Burns N.J., Williams B.C., Freestone S., Lee M.R. Blood and urine 5-hydroxytryptophan and 5-hydroxytryptamine levels after administration of two 5-hydroxytryptamine precursors in normal man. Br J Clin Pharmacol 1995, 39:327-329.
30. Paulmann N., Grohmann M., Voigt J.P., et al. Intracellular modulates insulin secretion from pancreatic beta-cells by protein serotonylation. PloS Biol 2009, 7:e1000229.
31. Lindström P. Kinetics of 5-hydroxytryptophan potentiation of glucose-induced insulin release. Acta Endocrinol (Copenh) 1984, 106:245-253.